DOCSLIB.ORG

THIORIDAZINE Thioridazinum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
THIORIDAZINE Thioridazinum EUROPEAN PHARMACOPOEIA 5.8 Thioridazine Detection: spectrophotometer at 240 nm. C. R = CO-C2H5 : testosterone propionate, Injection: 20 µl of the test solution and reference β D. R = CO-CH(CH3)2 : 3-oxoandrost-4-en-17 -yl solutions (a) and (b). 2-methylpropanoate (testosterone isobutyrate), Run time: twice the retention time of testosterone β isocaproate. E. R = CO-[CH2]4-CH3 : 3-oxoandrost-4-en-17 -yl hexanoate (testosterone caproate), Identification of impurities: use the chromatogram supplied with testosterone isocaproate for system suitability CRS F. R = CO-[CH2]5-CH3 : testosterone enantate, and the chromatogram obtained with reference solution (a) toidentifythepeaksduetoimpuritiesA,B,C,D,E,FandG. Relative retention with reference to testosterone isocaproate (retention time = about 14 min): impurity A = about 0.2; impurity B = about 0.4; impurity C = about 0.5; impurity D = about 0.7; impurity G = about 0.8; impurity E = about 1.1; impurity F = about 1.4. System suitability: reference solution (a): G. 3-oxoandrost-4-en-17α-yl 4-methylpentanoate — peak-to-valley ratio: minimum 2.5, where Hp =height abovethebaselineofthepeakduetoimpurityEand (epitestosterone isocaproate). Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to testosterone isocaproate. 07/2007:2005 Limits: — impurities A, B, C, D, E, F, G:foreachimpurity,notmore THIORIDAZINE than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent); Thioridazinum — unspecified impurities: for each impurity, not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent); — total: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent); — disregard limit: 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (b) C H N S M 370.6 (0.05 per cent). 21 26 2 2 r Free acid. Dissolve 0.44 g in 10 ml of ethanol (96 per DEFINITION cent) R, previously neutralised to bromothymol blue 10-[2-[(2RS)-1-Methylpiperidin-2-yl]ethyl]-2- solution R3, and titrate immediately with 0.01 M sodium (methylsulphanyl)-10H-phenothiazine hydroxide,using0.1mlofbromothymol blue solution R3 as Content: 99.0 per cent to 101.0 per cent (dried substance). indicator. Not more than 0.6 ml of 0.01 M sodium hydroxide is required to change the colour of the indicator to blue. CHARACTERS Loss on drying (2.2.32): maximum 0.5 per cent, determined Appearance:whiteoralmostwhitepowder. on 1.000 g over diphosphorus pentoxide R at a pressure Solubility: practically insoluble in water, very soluble in not exceeding 0.7 kPa. methylenechloride,freelysolubleinmethanol,solublein ethanol (96 per cent). ASSAY Liquid chromatography (2.2.29) as described in the test for IDENTIFICATION related substances with the following modification. Infrared absorption spectrophotometry (2.2.24). Injection: 20 µl of the test solution and reference solution (c). Comparison: thioridazine CRS. Calculate the percentage content of C H O from the 25 38 3 TESTS declared content of testosterone isocaproate CRS. Solution S. Dissolve 1.25 g in methanol R and dilute to IMPURITIES 25 ml with the same solvent. Specified impurities: A, B, C, D, E, F, G. Appearance of solution. Solution S is clear (2.2.1)andnot more intensely coloured than intensity 6 of the range of reference solutions of the most appropriate colour (2.2.2, Method II). Related substances.Liquidchromatography(2.2.29). Carry out the test as quickly as possible and protected from light. Test solution. Dissolve 20 mg of the substance to be examined in methanol R anddiluteto100mlwiththesame solvent. A. R = H: testosterone, Reference solution (a).Dilute5.0mlofthetestsolutionto β B. R =CO-CH3 : 3-oxoandrost-4-en-17 -yl acetate 100.0 ml with methanol R. Dilute 2.0 ml of this solution to (testosterone acetate), 100.0 ml with methanol R. GeneralNotices(1)applytoallmonographsandothertexts 5381 Tranexamic acid EUROPEAN PHARMACOPOEIA 5.8 Reference solution (b). Dissolve the contents of a vial ASSAY of thioridazine for system suitability CRS (containing Dissolve 0.300 g in 60 ml of anhydrous acetic acid R.Titrate impurities A, B, C, D and E) in 1.0 ml of methanol R. with 0.1 M perchloric acid, determining the end-point Column: potentiometrically (2.2.20). — size: l =0.25m,Ø=4.0mm; 1mlof0.1 M perchloric acid is equivalent to 37.06 mg of C H N S . — stationary phase: end-capped octadecylsilyl silica gel 21 26 2 2 for chromatography R resistant to bases up to pH 11. STORAGE Mobile phase: Protected from light. — mobile phase A: triethylamine R1, acetonitrile R, IMPURITIES water R (2:400:600 V/V/V); Specified impurities: A, B, C, D, E. — mobile phase B: triethylamine R1, acetonitrile R Other detectable impurities (the following substances (2:1000 V/V); would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited Time Mobile phase A Mobile phase B by the general acceptance criterion for other/unspecified (min) (per cent V/V) (per cent V/V) impurities and/or by the general monograph Substances for 0-5 100 0 pharmaceutical use (2034).Itisthereforenotnecessaryto 5 - 35 100 → 50→ 95 identify these impurities for demonstration of compliance. 35 - 40 5 95 See also 5.10. Control of impurities in substances for pharmaceutical use): F. 40 - 41 5 → 100 95 → 0 41 100 0 Flow rate:1.0ml/min. Detection: spectrophotometer at 275 nm. Injection:25µl. Identification of impurities:usethechromatogram supplied with thioridazine for system suitability CRS and ′ A. R = CH3,X=X =SO2 : 10-[2-[(2RS)-1-methylpiperidin- the chromatogram obtained with reference solution (b) to 2-yl]ethyl]-2-(methylsulphonyl)-10H-phenothiazine identify the peaks due to impurities A, B, C, D and E. 5,5-dioxide, Relative retention with reference to thioridazine ′ B. R = CH3,X=SO,X = S: 10-[2-[(2RS)-1-methylpiperidin- (retention time = about 30 min): impurity D = about 0.1; 2-yl]ethyl]-2-(methylsulphinyl)-10H-phenothiazine impurity A = about 0.3; impurity C = about 0.4; (mesoridazine), impurity B = about 0.5; impurity E = about 0.6. ′ System suitability: reference solution (b): C. R = CH3,X=S,X = SO: 10-[2-[(2RS)-1-methylpiperidin-2- yl]ethyl]-2-(methylsulphanyl)-10H-phenothiazine 5-oxide, — resolution : minimum 3.5 between the peaks due to ′ impurities C and B. D. R = CH3,X=X = SO: 10-[2-[(2RS)-1-methylpiperidin-2- yl]ethyl]-2-(methylsulphinyl)-10H-phenothiazine 5-oxide, Limits: ′ — correction factors: for the calculation of content, E. R = CH3,X=SO2,X = S: 10-[2-[(2RS)-1-methylpiperidin- multiply the peak areas of the following impurities by 2-yl]ethyl]-2-(methylsulphonyl)-10H-phenothiazine the corresponding correction factor: impurity A = 1.9; (sulforidazine), impurity B = 2.4; impurity C = 0.5; impurity D = 1.5; F. R = H, X = X′ = S: 2-(methylsulphanyl)-10-[2-[(2RS)- — impurities A, B, C, D, E: for each impurity, not more piperidin-2-yl]ethyl]-10H-phenothiazine (northioridazine). than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent); — unspecified impurities: for each impurity, not more 07/2007:0875 than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent); TRANEXAMIC ACID — total: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) Acidum tranexamicum (0.5 per cent); — disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent). Heavy metals (2.4.8): maximum 20 ppm. 1.0 g complies with test C. Prepare the reference solution using 2 ml of lead standard solution (10 ppm Pb) R. C8H15NO2 Mr 157.2 Loss on drying (2.2.32): maximum 0.5 per cent, determined on 1.000 g in vacuo at 50 °C for 4 h. DEFINITION Sulphated ash (2.4.14): maximum 0.1 per cent, determined trans-4-(Aminomethyl)cyclohexanecarboxylic acid. on 1.0 g. Content: 99.0 per cent to 101.0 per cent (dried substance). 5382 See the information section on general monographs (cover pages).
Load more

Recommended publications
  • Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Sander Delahaye
    Kinetic-Performance and Selectivity Optimization in Supercritical Fluid Chromatography Thesis Submitted to the Faculty of Science in Fulfilment of the Requirements for the Degree of Doctor in Science (Chemistry) Sander Delahaye Promotor Prof. Dr. Frédéric Lynen Leden van de lees- en examencommissie: Voorzitter: Prof. Dr. J. Martins Vakgroep Organische en Macromoleculaire Chemie, Faculteit Wetenschappen, UGent Leescommissie: Prof. Dr. K. Broeckhoven Vakgroep Chemische Ingenieurstechnieken en Industriële Scheikunde (CHIS), Faculteit Ingenieurswetenschappen, Vrije Universiteit Brussel Prof. Dr. D. Cabooter Laboratorium Farmaceutische Analyse, Faculteit Farmaceutische Wetenschappen, KU Leuven Dr. L. Balcaen Vakgroep Analytische Chemie, Faculteit Wetenschappen, UGent Examencommissie: Dr. I. Francois UPC²/SFC & Strategic Separation Technologies Business Development Manager Europe and India (Waters) Prof. Dr. K. Van Geem Vakgroep Chemische Proceskunde en Technische Chemie Faculteit Ingenieurswetenschappen en Architectuur, UGent Prof. Dr. F. Lynen Vakgroep Organische en Macromoleculaire Chemie, Faculteit Wetenschappen, UGent This research was funded by the Agency for Innovation by Science and Technology in Flanders (IWT - Vlaanderen) Table of Contents I General Introduction and Scope 1 1. General introduction . .1 2. Scope . .5 3. References . .6 II The Emergence of Packed-Column Supercritical Fluid Chromatography as an Alternative for HPLC 9 1. Introduction . 10 2. Definition of supercritical fluids . 10 3. Physico-chemical properties of supercritical fluids . 10 4. The use of supercritical fluids as extraction solvent and as mobile phase in chromatography . 15 5. SFC over the years . 16 6. Contemporary pSFC conditions and stationary phases . 17 7. Most important applications of supercritical fluid chromatography . 20 7.1. Preparative SFC applications . 20 7.2. Analytical SFC applications . 21 8. Nomenclature issues . 21 9.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Pharmacopoeial Reference Standards and Their Current Lot Numbers EP, EPISA, ICRS, BP July 2019
    Pharmacopoeial reference standards and their current lot numbers EP, EPISA, ICRS, BP July 2019 Mikromol Follow LGC on LinkedIn Dear user, This catalogue includes all pharmacopoeial reference materials from EP, EPISA, ICRS and BP available at LGC, as well as their current lot numbers. We update the catalogue on a monthly basis so that you can use the lot numbers to easily track the expiry dates of your stocked reference materials. We took the lot information from actual data from pharmacopoeias, correct at the time of production. We retained all spelling and information as provided by the pharmacopoeias. The list was compiled with caution, however, errors in this list may be possible, and LGC is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeial data, or from LGC during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical reference materials online at lgcstandards.com/mikromol. Stay connected via LinkedIn (LGC Mikromol) or Twitter @LGCMikromol. Kind regards Your LGC Standards Team LGC, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel: +44 (0)20 8943 8480 Fax: +44 (0)20 8943 7554 E-mail: mikromol@lgcgroup.com European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1
    [Show full text]
  • NEWS 02 2020 ENG.Qxp Layout 1
    Polymers and fluorescence Balance of power 360° drinking water analysis trilogy Fluorescence spectroscopy LCMS-8060NX: performance of industrial base polymers and robustness without Automatic, simultaneous and compromising sensitivity rapid analysis of pesticides and speed CONTENT APPLICATION »Plug und Play« disease screening solution? – The MALDI-8020 in screening for Sickle Cell Disease 4 Customized software solutions for any measurement – Macro programming for Shimadzu UV-Vis and FTIR 8 Ensuring steroid-free food supplements – Identification of steroids in pharmaceuticals and food supplements with LCMS-8045 11 MSn analysis of nonderivatized and Mtpp-derivatized peptides – Two recent studies applying LCMS-IT-TOF instruments 18 Polymers and fluorescence – Part 2: How much fluorescence does a polymer show during quality control? 26 PRODUCTS The balance of power – LCMS-8060NX balances enhanced performance and robustness 7 360° drinking water analysis: Episode 2 – Automatic, simul- taneous and rapid analysis of pesticides in drinking water by online SPE and UHPLC-MS/MS 14 Versatile testing tool for the automotive industry – Enrico Davoli with the PESI-MS system (research-use only [RUO] instrument) New HMV-G3 Series 17 No more headaches! A guide to choosing the perfect C18 column 22 Validated method for monoclonal antibody drugs – Assessment of the nSMOL methodology in Global solution through the validation of bevacizumab in human serum 24 global collaboration LATEST NEWS Global solution through global collaboration – Shimadzu Cancer diagnosis:
    [Show full text]
  • 9: Analytical Standards
    CATALOGUE NUMBER 9 ANALYTICAL STANDARDS Table of Contents Standards for Special Applications 3 Standards for Routine Analytical Applications 82 Certified Primary Pharmaceutical Standards 3 Environmental Standards 82 Certified GMO Materials 31 Particle Size Standards 115 Certified Clinical Chemistry Standards 33 Conductivity Standards 116 Other Certified Standards 34 Ion Chromatography Standards 116 Custom & OEM Standards 44 Redox Standards 117 Certified Industrial Raw Materials 44 Forensic & Veterinary Standards 117 Certified Drugs, Metabolites, & Impurities 45 Polymer Standards 126 Certified Food & Agriculture Standards 58 Petrochemical Standards 127 Proficiency Testing for Environmental Analysis 60 AAS/ICP Standards 130 Chromatography & CE Test Mixes 131 Selected Certified Reference Materials 64 TOC Standards 132 Environmental Standards 64 Melting Point Standards 132 Trace Cert Organics 75 Spectroscopy Standards—TraceCert 132 Occupational Hygiene Standards 76 MS Markers 134 Secondary Pharma Standards 76 Pharmaceutical & Clinical Standards 134 Titrimetric Substances 81 X-Ray Standards 135 Certified Spectroscopy Standards 81 Food & Beverage Standards 135 Gravimetry Standards 147 NMR Standards 147 Color Reference Solutions 148 Miscellaneous 148 NOTE: This publication is designed for electronic use only. Hazard and Safety information can be found on product detail pages and at sigma-aldrich.com/safetycenter. 2 Analytical Standards Technical Support: EURTechserv@sial.com Standards for Special Applications Certified Primary Pharmaceutical
    [Show full text]
  • Testosterone Dodecanoate III- Testosterone Caproate IV- Testosterone Dichloroacetate V- Testosterone Isocaproate VI- Testosterone Dipropionate
    Health Canada Santé Canada STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S) Substance: I- Testosterone caprylate II- Testosterone dodecanoate III- Testosterone caproate IV- Testosterone dichloroacetate V- Testosterone isocaproate VI- Testosterone dipropionate Based on the current information available to the Office of Controlled Substances, it appears that the above substance is: Controlled X Not Controlled ☐ under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s): The substances are derivatives of testosterone and are captured under sub-item 23(40) of Schedule IV to the CDSA. Prepared by: _______________________________________ Date: _______________ Vincent Marleau Verified by: _______________________________________ Date: ________________ Mark Kozlowski Approved by: _______________________________________ Date: ________________ DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES This status was requested by: Sahan de Silva, OCS 2 Drug Status Report Drugs: I- Testosterone caprylate II- Testosterone dodecanoate III- Testosterone caproate IV- Testosterone dichloroacetate V- Testosterone isocaproate VI- Testosterone dipropionate Drug Name Status: I- Testosterone caprylate II- Testosterone dodecanoate III- Testosterone caproate IV- Testosterone dichloroacetate V- Testosterone isocaproate VI- Testosterone dipropionate are the common names. Chemical Name: I- (8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17- tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl octanoate
    [Show full text]
  • United States Patent Office
    2,987,440 United States Patent Office Patented June 6, 1961 2 2,987,440 hitherto known had, in the non-crystalline state at room NJECTABLE HORMONE PREPARATIONS temperature, in practically all cases, the consistency of Karl Junkmann, Berlin, Josef Kathol, Berlin-Charlotten viscid resins or lacquers, whereas the melts produced ac burg, and Hans Richter, Berlin-Steglitz, Germany, as cording to the present invention, on cooling, crystallize signors to Schering A.G., Berlin, Germany, a corpora s only slowly and have the consistency of fluid oils. tion of Germany It was also in no way to be expected that it is possible No Drawing. Filed Mar. 17, 1958, Ser. No. 721,646 to produce physiologically effective hormone derivatives 2 Claims. (Cl. 167-65) with such low melting point. Their application, by means of a simple injection, constitutes an essential simplifica This invention relates to an injectable preparation com 10 tion, as compared with implantation, in the setting up of prising steroid hormones and/or non-steroid hormones comparatively large hormone depots in the organism. having the activity of such steroid hormones and more Further additions may be advantageously made in order particularly to an injectable preparation of a high con to dilute the hormone preparation so as to effect better centration in such steroid hormones and/or non-steroid dosage, since in setting up depots of less than about 100 hormones, said preparation being adapted to produce, on 5 mg., usually too great a proportion of an undesirable injection, a hormone depot of prolonged activity, and to hormone preparation remains behind in the injection a method of making such preparation.
    [Show full text]
  • EP USP EPISA ICRS BP Lot List 11122015 NL.Xlsx
    Lot lists of Pharmacopoeias EP, EPISA, ICRS, USP, BP December 2015 Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001756 Exemestane for system suitability 1 10 mg EPY0001561 Abacavir sulfate 1 20 mg EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1 10 mg EPY0000055 Acamprosate calcium - reference spectrum 1 n/a EPY0000116 Acamprosate impurity A 1 50 mg EPY0000500 Acarbose 3 100 mg EPY0000354 Acarbose for identification 1 10 mg EPY0000427 Acarbose for peak identification 3 20 mg EPA0040000 Acebutolol hydrochloride 1 50 mg EPY0000359 Acebutolol impurity B 2 10 mg EPY0000127 Acebutolol impurity C 1 20 mg EPY0000128 Acebutolol impurity I 2 0.004 mg EPY0000056 Aceclofenac - reference spectrum 1 n/a EPY0000085 Aceclofenac impurity F 2 15 mg EPY0000086 Aceclofenac impurity H 1 10 mg EPY0001094 Aceclofenac for peak identification 1 10 mg EPY0000810 Acemetacin 1 100 mg EPY0000811 Acemetacin impurity A 1 10 mg EPY0000842 Acemetacin impurity mixture 1 0.06 mg EPA0070000 Acesulfame potassium 2 50 mg EPA0070020 Acesulfame potassium impurity B 4 15 mg EPA0100000 Acetazolamide 1 100 mg EPY0001084 Acetazolamide for system suitability 2 0.0068 mg EPY0000002 Acetylcholine chloride 1 50 mg EPA0150000 Acetylcysteine 3 50 mg EPA0152000 Acetylcysteine impurity C 9 10 mg EPA0153000 Acetylcysteine impurity D 6 10 mg EPY0000565 ß-Acetyldigoxin 2 50 mg EPY0000642 ß-Acetyldigoxin for peak identification 1 10 mg EPA0200000 Acetylsalicylic acid 4 15 mg Follow us on Twitter @LGCStdsPharma December 2015 and LinkedIn at LGC Standards Pharma Pharmaceutical Lot List - NL Available Current Unit Cat.
    [Show full text]
  • Anabolic Steroids Ultimate Research Guide Vol. 1
    Anabolic Steroids Ultimate Research Guide Vol. 1 DISCLAIMER: Information contained within the Ultimate Research Guide is for entertainment purposes only. Although medical journals, textbooks, scientific articles, and information gathered from thousands of athletes were used to compile this book, we do not advise anyone to apply this information on themselves or other people. This information is strictly to show how others have used these drugs and should not be misinterpreted as medical advice. Neither the authors nor the publisher assumes any liability for the information presented in this book. We urge readers to consult with a physician and educate themselves on the laws of these drugs before using or obtaining them. Published by: Anabolic Information, LLC 7 Marina Dr. Montgomery, TX 77356 www.AnabolicBooks.com ISBN: 1-59975-100-3 Copyright© 2005 Anabolic Information, LLC No portion may be reproduced without the express written consent of the author. Table of Contents Preface & Dedication 7 Chapter 1 - Why Anabolic Steroids 8 Chapter 2 - How to read this book 10 Chapter 3 - An Introduction to your endocrine system 12 Chapter 4 - How anabolic steroids work 16 Chapter 5 - The game as it’s played 25 Chapter 6 - Injection techniques 31 Chapter 7 - Design your own cycles & Samples 34 Chapter 8 - Remove steroids in 5 days 39 Chapter 9 - Drug profiles 42 Testosterone Derived Steroids 46 Anabolicum vaster 48 Andriol 51 Androderm & Androgel 55 Andropen 275 59 Deposterona 62 Dianabol 64 Drive 68 Equilon 100 70 Equipoise 72 Halotestin 76 Megagrisevit
    [Show full text]
  • LGC Product List
    Uni-Asia Scientific Instrument Company Limited - Your Worldwide Laboratory Supplies Sourcing Partner Email sales@uniasiahk.com Website www.uniasiahk.com Please browse through our product lists or send your enquiry to sales@uniasiahk.com for a quotation! Bulk pricing can always be discussed! LGC Standards Product List Code Discriptions AC-SE015.040.001 Drugs of substitution STM 3/10-A SE serum, 6 x 2.5ml AC-SE015.040.002 Drugs of substitution STM 1/11-A SE serum, 6 x 2.5ml AC-SE015.040.005.003TDM Benzodiazepine in serum, lyophilised BZF 3/10-A SE for AC-SE015.040.005.004TDM Benzodiazepine in serum, lyophilised BZF 3/10-B SE for AC-SE015.040.005.005TDM Benzodiazepine in serum, lyophilised BZF 1/11– A SE for AC-SE015.040.005.006TDM Benzodiazepine in serum, lyophilised BZF 1/11– B SE for BAM-K008 Diesel oil (ISO 9377-2, ISO 16703, EN 14039), 7ml BAM-K009 Lubricating oil (ISO 9377-2, ISO 16703, EN 14039), 7ml BAM-K010 Diesel Fuel/Lubricating Oil (1:1) (ISO 9377-2, ISO 16703, BAMSUS-1R Setting-up sample for sectrometric analysis of low alloyed BCR-010 Tin ore powder - Tin; 225g BCR-017A Copper - Sulfur and phosphorous, 370g BCR-017B Copper - Sulfur and phosphorous; 50g BCR-022A Copper (electrolytic tough pitch) - Oxygen; 42g BCR-022B Copper (electrolytic tough pitch) - Oxygen; 28g BCR-024B Titanium - Oxygen and nitrogen; 10g BCR-024C Titanium - Oxygen, nitrogen; 5g BCR-032 Moroccan phosphate rock - Trace elements; 100g BCR-033 Super-phosphate - Constituents; 100g BCR-038 Fly ash from pulverised coal - Trace elements; 5g BCR-039B Pyrex glass
    [Show full text]
  • Lot Lists of Pharmacopoeias EP, EPISA, ICRS, USP, BP January 2016
    Lot lists of Pharmacopoeias EP, EPISA, ICRS, USP, BP January 2016 New: LGCon Standards LinkedIn Pharma Dear user, LGC Standards created this pharmacopoeial lot list for you from actual data from the Pharmacopoeais and correct at the time of production. We retained all spelling and information as provided by the Pharmacopoeias. The list was compiled with caution, however errors in this list may be possible, and LGC Standards is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeia data, or from LGC Standards during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical refer- ence materials online at www.lgcstandards.com. Stay connected via LinkedIn (LGC Standards Pharma) or Twitter @LGCStdsPharma Kind regards Your LGC Standards Team LGC Standards, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel.: +44 (0)20 8943 8480, Fax: +44 (0)20 8943 7554 E-Mail: pharma.tech@lgcgroup.com Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001756 Exemestane for system suitability 1 10 mg EPY0001561 Abacavir sulfate 1 20 mg EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1 10 mg EPY0000055 Acamprosate calcium - reference spectrum 1 n/a EPY0000116 Acamprosate impurity A 1 50 mg EPY0000500 Acarbose 3 100 mg EPY0000354 Acarbose for identification 1 10 mg
    [Show full text]
  • Distributeur Courtage Analyses Services 14 Rue De Mouettes 76130 Mont Saint Aignan Tel +33 (0) 2 35 07 60 00 Fax +33 (0)
    Contents Introduction ...........................................................................1 European Pharmacopoeia ....................................................3 International Commission on Pharmaceutical Enzymes.....43 British Pharmacopeia ..........................................................45 Pharmacopée Française .....................................................55 Japanese Pharmacopeia.....................................................58 National Institute of Health Sciences ..................................61 Pharmacopeia Helvetica......................................................62 International Pharmacopeia ................................................63 Institute of Dyes and Organic Products (IBPO) Poland .....68 Pharmaceutical Research Institute .....................................69 Refractive index CRMs ........................................................70 Pharmaceutical impurities ...................................................71 Pricing Information ............................................................105 Order Form........................................................................ 110 Introduction Introduction About R.T. Corporation (RTC) Established in 1988, RTC is a distributor of Pharmaceutical Reference Substances from the European Pharmacopoeia (EP), British Pharmacopoeia (BP) and other major pharmaceutical producers around the world. Since we are in the United States, it is easy to place and follow up an order by mail, telephone, fax and email. All orders are billed
    [Show full text]